
    
      This is a multicenter (when more than one hospital or medical school team work on a medical
      research study), open-label (all people know the identity of the intervention), randomized
      (the study drug is assigned by chance), parallel-group (Each group of participants will be
      treated at the same time), comparison study to assess the pharmacokinetics and safety of
      paliperidone palmitate (study medication) in participants with schizophrenia. The study
      comprises a 64-day Treatment period and a 155-day Follow-up period. The participants will be
      randomly assigned to one of the four study groups. The study medication will be administered
      on Days 1, 8, 36 and 64. Pharmacokinetics of the study medication will be assessed as primary
      outcome. Participants' safety will be monitored throughout the study.
    
  